Liu-Chang Zheng, Fang Liu, Pei-Ming Zheng, Zheng Xiao, Fa-Cai Cui
{"title":"老年心肌梗死患者血清sST2、IL-33和Hcy表达及其对MACE的预测价值","authors":"Liu-Chang Zheng, Fang Liu, Pei-Ming Zheng, Zheng Xiao, Fa-Cai Cui","doi":"10.2147/CIA.S519437","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Acute myocardial infarction (AMI) in the elderly is associated with high morbidity and mortality, with major adverse cardiovascular events (MACE) remaining a major concern despite early revascularization. This study aimed to evaluate the association of soluble suppression of tumorigenicity 2 (sST2), interleukin-33 (IL-33), and homocysteine (Hcy) with coronary stenosis severity and their predictive value for MACE in elderly AMI patients.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 143 elderly AMI patients (≥65 years) admitted between June 2022 and June 2024. Patients were divided into two groups based on MACE occurrence: Group A (no MACE, n=56) and Group B (MACE, n=87). Serum sST2, IL-33, and Hcy levels were measured using ELISA, and coronary stenosis severity was assessed using the Gensini score. Statistical analyses included Spearman correlation, multivariate logistic regression, and receiver operating characteristic (ROC) curve analysis to evaluate predictive performance.</p><p><strong>Results: </strong>Serum sST2, IL-33, and Hcy levels were significantly higher in the MACE group compared to the non-MACE group (72.37±10.68 vs 38.76±11.15, p<0.05; 60.61±10.89 vs 33.74±11.23, p<0.05; 32.76±4.15 vs 15.38±4.62, p<0.05, respectively). Biomarker levels positively correlated with coronary stenosis severity (sST2: r=0.647, p<0.05; IL-33: r=0.659, p<0.05; Hcy: r=0.582, p<0.05). Multivariate logistic regression confirmed that sST2 (OR=1.056, 95% CI: 1.015-1.094, p=0.005), IL-33 (OR=1.069, 95% CI: 1.024-2.016, p=0.001), and Hcy (OR=1.037, 95% CI: 1.008-1.077, p=0.033) were independent risk factors for MACE. ROC analysis showed that sST2, IL-33, and Hcy had AUCs of 0.841 (95% CI: 0.762-0.915, p<0.001), 0.803 (95% CI: 0.724-0.878, p<0.001), and 0.729 (95% CI: 0.642-0.812, p<0.001), respectively. Combined detection of all three biomarkers significantly improved MACE prediction (AUC=0.910, 95% CI: 0.851-0.956, p<0.001).</p><p><strong>Conclusion: </strong>Serum sST2, IL-33, and Hcy levels are positively correlated with coronary stenosis severity and independently associated with MACE in elderly AMI patients. Their combined detection significantly enhances MACE prediction, providing a potential strategy for improved risk stratification and management in this high-risk population.</p>","PeriodicalId":48841,"journal":{"name":"Clinical Interventions in Aging","volume":"20 ","pages":"495-504"},"PeriodicalIF":3.5000,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12039929/pdf/","citationCount":"0","resultStr":"{\"title\":\"Serum sST2, IL-33, and Hcy Expression in Older Adults Patients with Myocardial Infarction and Their Predictive Value for MACE.\",\"authors\":\"Liu-Chang Zheng, Fang Liu, Pei-Ming Zheng, Zheng Xiao, Fa-Cai Cui\",\"doi\":\"10.2147/CIA.S519437\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Acute myocardial infarction (AMI) in the elderly is associated with high morbidity and mortality, with major adverse cardiovascular events (MACE) remaining a major concern despite early revascularization. This study aimed to evaluate the association of soluble suppression of tumorigenicity 2 (sST2), interleukin-33 (IL-33), and homocysteine (Hcy) with coronary stenosis severity and their predictive value for MACE in elderly AMI patients.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 143 elderly AMI patients (≥65 years) admitted between June 2022 and June 2024. Patients were divided into two groups based on MACE occurrence: Group A (no MACE, n=56) and Group B (MACE, n=87). Serum sST2, IL-33, and Hcy levels were measured using ELISA, and coronary stenosis severity was assessed using the Gensini score. Statistical analyses included Spearman correlation, multivariate logistic regression, and receiver operating characteristic (ROC) curve analysis to evaluate predictive performance.</p><p><strong>Results: </strong>Serum sST2, IL-33, and Hcy levels were significantly higher in the MACE group compared to the non-MACE group (72.37±10.68 vs 38.76±11.15, p<0.05; 60.61±10.89 vs 33.74±11.23, p<0.05; 32.76±4.15 vs 15.38±4.62, p<0.05, respectively). Biomarker levels positively correlated with coronary stenosis severity (sST2: r=0.647, p<0.05; IL-33: r=0.659, p<0.05; Hcy: r=0.582, p<0.05). Multivariate logistic regression confirmed that sST2 (OR=1.056, 95% CI: 1.015-1.094, p=0.005), IL-33 (OR=1.069, 95% CI: 1.024-2.016, p=0.001), and Hcy (OR=1.037, 95% CI: 1.008-1.077, p=0.033) were independent risk factors for MACE. ROC analysis showed that sST2, IL-33, and Hcy had AUCs of 0.841 (95% CI: 0.762-0.915, p<0.001), 0.803 (95% CI: 0.724-0.878, p<0.001), and 0.729 (95% CI: 0.642-0.812, p<0.001), respectively. Combined detection of all three biomarkers significantly improved MACE prediction (AUC=0.910, 95% CI: 0.851-0.956, p<0.001).</p><p><strong>Conclusion: </strong>Serum sST2, IL-33, and Hcy levels are positively correlated with coronary stenosis severity and independently associated with MACE in elderly AMI patients. Their combined detection significantly enhances MACE prediction, providing a potential strategy for improved risk stratification and management in this high-risk population.</p>\",\"PeriodicalId\":48841,\"journal\":{\"name\":\"Clinical Interventions in Aging\",\"volume\":\"20 \",\"pages\":\"495-504\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-04-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12039929/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Interventions in Aging\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/CIA.S519437\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"GERIATRICS & GERONTOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Interventions in Aging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/CIA.S519437","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:老年人急性心肌梗死(AMI)与高发病率和死亡率相关,尽管早期血运重建术,但主要不良心血管事件(MACE)仍然是一个主要问题。本研究旨在评估可溶性抑制致瘤性2 (sST2)、白细胞介素-33 (IL-33)和同型半胱氨酸(Hcy)与老年AMI患者冠状动脉狭窄严重程度的关系及其对MACE的预测价值。方法:对我院2022年6月至2024年6月收治的143例老年AMI患者(≥65岁)进行回顾性分析。根据MACE发生情况将患者分为两组:A组(无MACE, n=56)和B组(有MACE, n=87)。ELISA法检测血清sST2、IL-33和Hcy水平,Gensini评分法评估冠状动脉狭窄严重程度。统计分析包括Spearman相关、多元logistic回归和受试者工作特征(ROC)曲线分析来评估预测效果。结果:MACE组患者血清sST2、IL-33、Hcy水平显著高于非MACE组(72.37±10.68 vs 38.76±11.15)。结论:老年AMI患者血清sST2、IL-33、Hcy水平与冠脉狭窄严重程度呈正相关,且与MACE独立相关。他们的联合检测显着提高了MACE预测,为改善高危人群的风险分层和管理提供了潜在的策略。
Serum sST2, IL-33, and Hcy Expression in Older Adults Patients with Myocardial Infarction and Their Predictive Value for MACE.
Objective: Acute myocardial infarction (AMI) in the elderly is associated with high morbidity and mortality, with major adverse cardiovascular events (MACE) remaining a major concern despite early revascularization. This study aimed to evaluate the association of soluble suppression of tumorigenicity 2 (sST2), interleukin-33 (IL-33), and homocysteine (Hcy) with coronary stenosis severity and their predictive value for MACE in elderly AMI patients.
Methods: A retrospective analysis was conducted on 143 elderly AMI patients (≥65 years) admitted between June 2022 and June 2024. Patients were divided into two groups based on MACE occurrence: Group A (no MACE, n=56) and Group B (MACE, n=87). Serum sST2, IL-33, and Hcy levels were measured using ELISA, and coronary stenosis severity was assessed using the Gensini score. Statistical analyses included Spearman correlation, multivariate logistic regression, and receiver operating characteristic (ROC) curve analysis to evaluate predictive performance.
Results: Serum sST2, IL-33, and Hcy levels were significantly higher in the MACE group compared to the non-MACE group (72.37±10.68 vs 38.76±11.15, p<0.05; 60.61±10.89 vs 33.74±11.23, p<0.05; 32.76±4.15 vs 15.38±4.62, p<0.05, respectively). Biomarker levels positively correlated with coronary stenosis severity (sST2: r=0.647, p<0.05; IL-33: r=0.659, p<0.05; Hcy: r=0.582, p<0.05). Multivariate logistic regression confirmed that sST2 (OR=1.056, 95% CI: 1.015-1.094, p=0.005), IL-33 (OR=1.069, 95% CI: 1.024-2.016, p=0.001), and Hcy (OR=1.037, 95% CI: 1.008-1.077, p=0.033) were independent risk factors for MACE. ROC analysis showed that sST2, IL-33, and Hcy had AUCs of 0.841 (95% CI: 0.762-0.915, p<0.001), 0.803 (95% CI: 0.724-0.878, p<0.001), and 0.729 (95% CI: 0.642-0.812, p<0.001), respectively. Combined detection of all three biomarkers significantly improved MACE prediction (AUC=0.910, 95% CI: 0.851-0.956, p<0.001).
Conclusion: Serum sST2, IL-33, and Hcy levels are positively correlated with coronary stenosis severity and independently associated with MACE in elderly AMI patients. Their combined detection significantly enhances MACE prediction, providing a potential strategy for improved risk stratification and management in this high-risk population.
期刊介绍:
Clinical Interventions in Aging, is an online, peer reviewed, open access journal focusing on concise rapid reporting of original research and reviews in aging. Special attention will be given to papers reporting on actual or potential clinical applications leading to improved prevention or treatment of disease or a greater understanding of pathological processes that result from maladaptive changes in the body associated with aging. This journal is directed at a wide array of scientists, engineers, pharmacists, pharmacologists and clinical specialists wishing to maintain an up to date knowledge of this exciting and emerging field.